Rehman B, Ahmed A, Khan S, Saleem N, Naseer F, Ahmad S
Trop Dis Travel Med Vaccines. 2024; 10(1):23.
PMID: 39543749
PMC: 11566162.
DOI: 10.1186/s40794-024-00232-1.
Tin Ern N, Komarasamy T, Adnan N, Balasubramaniam V
Am J Trop Med Hyg. 2024; 112(1):37-44.
PMID: 39531732
PMC: 11720763.
DOI: 10.4269/ajtmh.23-0545.
Chauhan N, Gaur K, Asuru T, Guchhait P
Biosci Rep. 2024; 44(8).
PMID: 39051974
PMC: 11327219.
DOI: 10.1042/BSR20240134.
Natali E, Horst A, Meier P, Greiff V, Nuvolone M, Babrak L
NPJ Vaccines. 2024; 9(1):16.
PMID: 38245547
PMC: 10799860.
DOI: 10.1038/s41541-023-00788-7.
McCormack C, Goethals O, Goeyvaerts N, Woot de Trixhe X, Geluykens P, Borrenberghs D
PLoS Comput Biol. 2023; 19(12):e1011662.
PMID: 38055683
PMC: 10699615.
DOI: 10.1371/journal.pcbi.1011662.
Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19.
Tripp R, Martin D
Viruses. 2023; 15(11).
PMID: 38005930
PMC: 10675723.
DOI: 10.3390/v15112254.
Antiviral Activity of an Indole-Type Compound Derived from Natural Products, Identified by Virtual Screening by Interaction on Dengue Virus NS5 Protein.
Garcia-Ariza L, Gonzalez-Rivillas N, Diaz-Aguirre C, Rocha-Roa C, Padilla-Sanabria L, Castano-Osorio J
Viruses. 2023; 15(7).
PMID: 37515249
PMC: 10384440.
DOI: 10.3390/v15071563.
Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers.
Ackaert O, Vanhoutte F, Verpoorten N, Buelens A, Lachau-Durand S, Lammens L
Clin Infect Dis. 2023; 77(6):857-865.
PMID: 37161721
PMC: 10506772.
DOI: 10.1093/cid/ciad284.
Molecular Mechanisms of Antiviral Agents against Dengue Virus.
Lee M, Wu Y, Poh C
Viruses. 2023; 15(3).
PMID: 36992414
PMC: 10056858.
DOI: 10.3390/v15030705.
Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates.
Goethals O, Kaptein S, Kesteleyn B, Bonfanti J, Van Wesenbeeck L, Bardiot D
Nature. 2023; 615(7953):678-686.
PMID: 36922586
PMC: 10033419.
DOI: 10.1038/s41586-023-05790-6.
Assessing the potential of NS2B/NS3 protease inhibitors biomarker in curbing dengue virus infections: vs. approach.
Norshidah H, Leow C, Ezleen K, Wahab H, Vignesh R, Rasul A
Front Cell Infect Microbiol. 2023; 13:1061937.
PMID: 36864886
PMC: 9971573.
DOI: 10.3389/fcimb.2023.1061937.
Pharmacophore-Model-Based Drug Repurposing for the Identification of the Potential Inhibitors Targeting the Allosteric Site in Dengue Virus NS5 RNA-Dependent RNA Polymerase.
Kumar S, Bajrai L, Faizo A, Khateb A, Alkhaldy A, Rana R
Viruses. 2022; 14(8).
PMID: 36016449
PMC: 9412353.
DOI: 10.3390/v14081827.
Structures and Dynamics of Dengue Virus Nonstructural Membrane Proteins.
Li Q, Kang C
Membranes (Basel). 2022; 12(2).
PMID: 35207152
PMC: 8880049.
DOI: 10.3390/membranes12020231.
Phytochemical Compound Screening to Identify Novel Small Molecules against Dengue Virus: A Docking and Dynamics Study.
Shimu M, Mahmud S, Tallei T, Sami S, Adam A, Acharjee U
Molecules. 2022; 27(3).
PMID: 35163918
PMC: 8840231.
DOI: 10.3390/molecules27030653.
Evaluation of AT-752, a Double Prodrug of a Guanosine Nucleotide Analog with and Activity against Dengue and Other Flaviviruses.
Good S, Shannon A, Lin K, Moussa A, Julander J, La Colla P
Antimicrob Agents Chemother. 2021; 65(11):e0098821.
PMID: 34424050
PMC: 8522752.
DOI: 10.1128/AAC.00988-21.
A Bibliometric Analysis on Dengue Outbreaks in Tropical and Sub-Tropical Climates Worldwide Since 1950.
Liu S, Chien T, Yang T, Yeh Y, Chou W, Chow J
Int J Environ Res Public Health. 2021; 18(6).
PMID: 33808795
PMC: 8003706.
DOI: 10.3390/ijerph18063197.
Recent progress on phenotype-based discovery of dengue inhibitors.
Yokokawa F
RSC Med Chem. 2021; 11(5):541-551.
PMID: 33479655
PMC: 7593893.
DOI: 10.1039/d0md00052c.